{"id":"vincristine-and-topotecan","safety":{"commonSideEffects":[{"rate":"40-60%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vincristine works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Topotecan, on the other hand, inhibits topoisomerase I, an enzyme that unwinds DNA during replication. By inhibiting this enzyme, Topotecan prevents DNA replication and induces apoptosis in cancer cells.","oneSentence":"Vincristine is a vinca alkaloid that inhibits microtubule formation, while Topotecan is a topoisomerase I inhibitor that prevents DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:43.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia"},{"name":"Small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT06647953","phase":"PHASE3","title":"Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-03-21","conditions":"Pleuropulmonary Blastoma","enrollment":110},{"nctId":"NCT04322318","phase":"PHASE2","title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-10-19","conditions":"Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor","enrollment":256},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT01231906","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2010-11-24","conditions":"Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues","enrollment":642},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT07321912","phase":"PHASE2","title":"Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-04-01","conditions":"Osteosarcoma, Ewing Sarcoma, Ewing Sarcoma Metastatic","enrollment":406},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT04681417","phase":"PHASE2, PHASE3","title":"Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2021-03-25","conditions":"Retinoblastoma","enrollment":225},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT00186888","phase":"PHASE3","title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04-07","conditions":"Retinoblastoma, Retinal Neoplasm","enrollment":107},{"nctId":"NCT04947501","phase":"EARLY_PHASE1","title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-06-22","conditions":"Neuroblastoma, Pediatric Cancer","enrollment":26},{"nctId":"NCT06933394","phase":"PHASE2","title":"Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-05-01","conditions":"Neuroblastoma","enrollment":92},{"nctId":"NCT06669013","phase":"PHASE3","title":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2021-05-20","conditions":"Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma","enrollment":40},{"nctId":"NCT01798004","phase":"PHASE1","title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-09","conditions":"Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma","enrollment":150},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT01606878","phase":"PHASE1","title":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-29","conditions":"Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma","enrollment":46},{"nctId":"NCT06088030","phase":"PHASE2","title":"Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer","status":"RECRUITING","sponsor":"Yang Li","startDate":"2023-12-13","conditions":"Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations","enrollment":50},{"nctId":"NCT03236857","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-08","conditions":"Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)","enrollment":143},{"nctId":"NCT00567567","phase":"PHASE3","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-11-05","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":665},{"nctId":"NCT02566993","phase":"PHASE3","title":"Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2016-08-30","conditions":"Small-cell Lung Cancer","enrollment":613},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02786719","phase":"NA","title":"High-Risk Neuroblastoma Chemotherapy Without G-CSF","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-06","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT00877110","phase":"PHASE1","title":"Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-04-02","conditions":"Neuroblastoma, Bone Marrow, Sympathetic Nervous System","enrollment":71},{"nctId":"NCT00980551","phase":"NA","title":"Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma","status":"WITHDRAWN","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-05","conditions":"Retinoblastoma","enrollment":""},{"nctId":"NCT03042429","phase":"PHASE3","title":"Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2007-01-01","conditions":"Neuroblastoma","enrollment":360},{"nctId":"NCT00526318","phase":"NA","title":"Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma","status":"UNKNOWN","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2007-01","conditions":"Neuroblastoma","enrollment":360},{"nctId":"NCT00618813","phase":"NA","title":"Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-03","conditions":"Ewing Sarcoma of Bone, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":35},{"nctId":"NCT00516295","phase":"PHASE2","title":"Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02","conditions":"Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor","enrollment":7},{"nctId":"NCT00070200","phase":"PHASE1","title":"Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-03","conditions":"Neuroblastoma","enrollment":31},{"nctId":"NCT00392340","phase":"PHASE2","title":"Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2008-03","conditions":"Neuroblastoma","enrollment":63},{"nctId":"NCT00379457","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma","status":"UNKNOWN","sponsor":"European Paediatric Soft Tissue Sarcoma Study Group","startDate":"2006-06","conditions":"Sarcoma","enrollment":600},{"nctId":"NCT00410631","phase":"PHASE3","title":"Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma","status":"UNKNOWN","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2004-10","conditions":"Neuroblastoma","enrollment":642},{"nctId":"NCT00334867","phase":"PHASE3","title":"Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2005-12","conditions":"Sarcoma","enrollment":""},{"nctId":"NCT00003958","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2002-09","conditions":"Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma","enrollment":702},{"nctId":"NCT00004188","phase":"PHASE3","title":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2001-02","conditions":"Neuroblastoma","enrollment":495},{"nctId":"NCT00040872","phase":"PHASE2","title":"Multiple Therapies in Treating Patients With Advanced Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-06","conditions":"Neuroblastoma","enrollment":""},{"nctId":"NCT00002643","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-04","conditions":"Neutropenia, Sarcoma","enrollment":130},{"nctId":"NCT00003211","phase":"PHASE2","title":"Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"1996-10","conditions":"Brain and Central Nervous System Tumors","enrollment":94},{"nctId":"NCT00001335","phase":"PHASE2","title":"New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-04","conditions":"Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oncovin + Hycamtin"],"phase":"phase_3","status":"active","brandName":"Vincristine and Topotecan","genericName":"Vincristine and Topotecan","companyName":"St. Jude Children's Research Hospital","companyId":"st-jude-children-s-research-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vincristine is a vinca alkaloid that inhibits microtubule formation, while Topotecan is a topoisomerase I inhibitor that prevents DNA replication. Used for Acute lymphoblastic leukemia, Small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}